Literature DB >> 1501299

The C terminus of human immunodeficiency virus type 1 matrix protein is involved in early steps of the virus life cycle.

X Yu1, Q C Yu, T H Lee, M Essex.   

Abstract

Deletion mutations at the C terminus of the matrix (MA) protein of human immunodeficiency virus type 1 (HIV-1) were generated by site-directed mutagenesis. The resultant mutant viruses had a severe defect in virus infectivity. This defect did not involve late steps of the virus life cycle, as the synthesis and processing of the Gag polyprotein and the assembly and release of mutant virions were not greatly affected. The incorporation of viral proteins and the viral RNA genome was similar for mutant and wild-type virions. In contrast, the early steps of the virus life cycle were severely affected, as the synthesis of viral DNA postinfection was dramatically reduced in mutant-virus-infected cells. One stretch of amino acids that was deleted in one of the mutants has significant homology with a region in VP1 of the picornavirus family. This region of VP1 is presumably involved in poliovirus penetration into cells. These results suggest that in addition to its functional role in virus assembly, the MA protein of HIV-1, and possibly of other retroviruses, plays an important role in virus entry.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1501299      PMCID: PMC289135     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  26 in total

1.  Structural role of the matrix protein of type D retroviruses in gag polyprotein stability and capsid assembly.

Authors:  S S Rhee; E Hunter
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

2.  A sequence in the carboxyl terminus of the HIV-1 matrix protein is highly similar to sequences in membrane-associated proteins of other RNA viruses: possible functional implications.

Authors:  J Blomberg; P Medstrand
Journal:  New Biol       Date:  1990-11

3.  The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions.

Authors:  X Yu; X Yuan; Z Matsuda; T H Lee; M Essex
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

4.  Suppression of retroviral MA deletions by the amino-terminal membrane-binding domain of p60src.

Authors:  J W Wills; R C Craven; R A Weldon; T D Nelle; C R Erdie
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

5.  Detection of specific sequences among DNA fragments separated by gel electrophoresis.

Authors:  E M Southern
Journal:  J Mol Biol       Date:  1975-11-05       Impact factor: 5.469

6.  Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1.

Authors:  H G Göttlinger; J G Sodroski; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

7.  Myristylation is required for intracellular transport but not for assembly of D-type retrovirus capsids.

Authors:  S S Rhee; E Hunter
Journal:  J Virol       Date:  1987-04       Impact factor: 5.103

8.  Mutations in gag proteins P12 and P15 of Moloney murine leukemia virus block early stages of infection.

Authors:  S Crawford; S P Goff
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

9.  Factors affecting cellular tropism of human immunodeficiency virus.

Authors:  S Kim; K Ikeuchi; J Groopman; D Baltimore
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

10.  Amino acid substitutions within the matrix protein of type D retroviruses affect assembly, transport and membrane association of a capsid.

Authors:  S S Rhee; E Hunter
Journal:  EMBO J       Date:  1991-03       Impact factor: 11.598

View more
  54 in total

1.  Reversion of a human immunodeficiency virus type 1 matrix mutation affecting Gag membrane binding, endogenous reverse transcriptase activity, and virus infectivity.

Authors:  R E Kiernan; A Ono; E O Freed
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

2.  Somatic cell mutants resistant to retrovirus replication: intracellular blocks during the early stages of infection.

Authors:  G Gao; S P Goff
Journal:  Mol Biol Cell       Date:  1999-06       Impact factor: 4.138

3.  Construction and characterization of a fluorescently labeled infectious human immunodeficiency virus type 1 derivative.

Authors:  Barbara Müller; Jessica Daecke; Oliver T Fackler; Matthias T Dittmar; Hanswalter Zentgraf; Hans-Georg Kräusslich
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

4.  Characterization of replication defects induced by mutations in the basic domain and C-terminus of HIV-1 matrix.

Authors:  Ajay K Bhatia; Nancy Campbell; Antonito Panganiban; Lee Ratner
Journal:  Virology       Date:  2007-08-13       Impact factor: 3.616

5.  A large region within the Rous sarcoma virus matrix protein is dispensable for budding and infectivity.

Authors:  T D Nelle; J W Wills
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

6.  Assembly, processing, and infectivity of human immunodeficiency virus type 1 gag mutants.

Authors:  C T Wang; E Barklis
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

7.  Role of the matrix protein in the virion association of the human immunodeficiency virus type 1 envelope glycoprotein.

Authors:  T Dorfman; F Mammano; W A Haseltine; H G Göttlinger
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

8.  Functional exchange of an oncoretrovirus and a lentivirus matrix protein.

Authors:  C A Deminie; M Emerman
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

9.  Multiple functions for the basic amino acids of the human T-cell leukemia virus type 1 matrix protein in viral transmission.

Authors:  I Le Blanc; A R Rosenberg; M C Dokhélar
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 protease triggers a myristoyl switch that modulates membrane binding of Pr55(gag) and p17MA.

Authors:  L Hermida-Matsumoto; M D Resh
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.